nach oben

Erschienen in:

01.08.2015 | Review

The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review

verfasst von: Argiri Sianou, George Galyfos, Dimitra Moragianni, Panagiotis Andromidas, Georgios Kaparos, Stavroula Baka, Evangelia Kouskouni

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Epigenetics seem to play a primary role in the current research on the pathogenesis of different types of endometrial cancer. Data so far indicate that microRNAs regulate different pathways that could lead to carcinogenesis when not functioning properly. The aim of this review is to summarize current knowledge on microRNAs that have been associated with endometrial cancer development.

Material and Methods

From July 2014 to August 2014, we conducted a comprehensive research utilizing major online search engines (Pubmed, Crossref, Google Scholar). The main keywords used in our search were endometrial cancer/carcinoma; microRNA; epigenetics; novel biomarkers; pathogenesis.

Results

Overall, we identified 155 studies, although only 77 were eligible for this review. Different miRNAs were identified to contribute either promoting the carcinogenesis in the endometrium or inhibiting different steps of endometrial cancer development. Tumour growth, cell proliferation, apoptosis and invasion metastasis have been identified as the main processes where miRNAs seem to be implicated.

Conclusions

microRNAs are effective regulators of gene expression that has a significant role in the pathogenesis of endometrial cancer. Research concerning possible therapeutic implications has been promising, although there is still a significant distance to be covered between research observations and clinical results. Extensive preclinical and translational research is still required to improve the efficacy and minimize unwanted effects of miRNAs-based therapy.

Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111:436–447PubMed

Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783–4791PubMed

Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. Lancet Oncol 15:e268–e278PubMed

Olivieri F, Rippo MR, Monsurrò V, Salvioli S, Capri M, Procopio AD (2013) MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev 12:1056–1068PubMed

Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H (2005) Stem cell division is regulated by the microRNA pathway. Nature 435:974–978PubMed

Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33:1290–1297PubMedCentralPubMed

Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG (2014) Epigenetic inactivation of DNA repair in breast cancer. Cancer Lett 342:213–222PubMed

Balch C, Matei DE, Huang TH, Nephew KP (2010) Role of epigenomics in ovarian and endometrial cancers. Epigenomics 2:419–447PubMed

Torres A, Torres K, Paszkowski T, Jodłowska-Jędrych B, Radomański T, Ksiazek A et al (2011) Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer. Tumour Biol 32:769–776PubMedCentralPubMed

10.

Gordon LK, Kiyohara M, Fu M, Braun J, Dhawan P, Chan A et al (2013) EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF. Oncogene 32:5369–5376PubMedCentralPubMed

11.

Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, Estellés A et al (2012) microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod 27:3036–3045PubMed

12.

Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J et al (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23:2700–2704PubMedCentralPubMed

13.

Chiappinelli KB, Haynes BC, Brent MR, Goodfellow PJ (2012) Reduced DICER1 elicits an interferon response in endometrial cancer cells. Mol Cancer Res 10:316–325PubMedCentralPubMed

14.

Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X et al (2013) miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol 30:484PubMed

15.

Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y, Choi C et al (2012) The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol 124:125–133PubMed

16.

Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF et al (2009) Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124:1358–1365PubMed

17.

Su N, Qiu H, Chen Y, Yang T, Yan Q, Wan X (2013) miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep 29:2297–2302PubMed

18.

Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON et al (2013) Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 12:2917–2928PubMedCentralPubMed

19.

McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA et al (2014) Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 27:128–134PubMedCentralPubMed

20.

Qin X, Yan L, Zhao X, Li C, Fu Y (2012) microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer. Oncol Lett 4:1290–1296PubMedCentralPubMed

21.

Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H et al (2011) MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 11:425PubMedCentralPubMed

22.

Guo Y, Liao Y, Jia C, Ren J, Wang J, Li T (2013) MicroRNA-182 promotes tumor cell growth by targeting transcription elongation factor A-like 7 in endometrial carcinoma. Cell Physiol Biochem 32:581–590PubMed

23.

Yang Y, Zhou L, Lu L, Wang L, Li X, Jiang P et al (2013) A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene 32:3432–3442PubMed

24.

Liu B, Che Q, Qiu H, Bao W, Chen X, Lu W et al (2014) Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα. PLoS One 9:e87563PubMedCentralPubMed

25.

Dorjgochoo T, Xiang YB, Long J, Shi J, Deming S, Xu WH et al (2013) Association of genetic markers in the BCL-2 family of apoptosis-related genes with endometrial cancer risk in a Chinese population. PLoS One 8:e60915PubMedCentralPubMed

26.

Antonsson B, Martinou JC (2000) The Bcl-2 protein family. Exp Cell Res 256:50–57PubMed

27.

Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H et al (2012) Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett 314:155–165PubMed

28.

Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B et al (2008) Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27:9–19PubMed

29.

Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L et al (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70:367–377PubMedCentralPubMed

30.

Mozos A, Catasús L, D’Angelo E, Serrano E, Espinosa I, Ferrer I et al (2014) The FOXO1–miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. Hum Pathol 45:942–951PubMed

31.

Van der Zee M, Jia Y, Wang Y, Heijmans-Antonissen C, Ewing PC, Franken P et al (2013) Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression. J Pathol 230:48–58PubMed

32.

Zhang G, Hou X, Li Y, Zhao M (2014) MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer 14:440PubMedCentralPubMed

33.

Zhao ZN, Bai JX, Zhou Q, Yan B, Qin WW, Jia LT et al (2012) TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One 7:e45133PubMedCentralPubMed

34.

Gilani S, Anderson I, Fathallah L, Mazzara P (2014) Factors predicting nodal metastasis in endometrial cancer. Arch Gynecol Obstet 290:1187–1193PubMed

35.

Yang L, Shen X, Li J, Yang J, Le Y, Gong Z (2014) MicroRNAs affect tumor metastasis through regulating epithelial–mesenchymal transition. Yi Chuan 36:637–645PubMed

36.

Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E et al (2012) The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 14:715–720PubMed

37.

Li BL, Lu W, Lu C, Qu JJ, Yang TT, Yan Q et al (2013) CpG island hypermethylation-associated silencing of microRNAs promotes human endometrial cancer. Cancer Cell Int 13:44PubMedCentralPubMed

38.

Snowdon J, Zhang X, Childs T, Tron VA, Feilotter H (2011) The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 6:e22828PubMedCentralPubMed

39.

Dai Y, Xia W, Song T, Su X, Li J, Li S et al (2013) MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells. Nucleic Acid Ther 23:29–34PubMedCentralPubMed

40.

Hiroki E, Akahira JI, Suzuki F, Nagase S, Ito K, Suzuki T et al (2009) Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101:241–249PubMed

41.

Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE et al (2014) A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74:15–23PubMedCentralPubMed

42.

Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371–377PubMed

43.

Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P et al (2012) Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 12:369PubMedCentralPubMed

44.

Taskiran C, Erdem O, Onan A, Vural C, Arisoy O, Yildiz S et al (2014) Maspin expression in endometrial hyperplasia and carcinoma, and its relation with angiogenesis. Eur J Gynaecol Oncol 35:134–139PubMed

45.

Torres A, Torres K, Paszkowski T, Radej S, Staśkiewicz GJ, Ceccaroni M et al (2011) Highly increased maspin expression corresponds with up-regulation of miR-21 in endometrial cancer: a preliminary report. Int J Gynecol Cancer 21:8–14PubMed

46.

Wang L, Guo ZY, Zhang R, Xin B, Chen R, Zhao J et al (2013) Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis 34:1773–1781PubMed

47.

Wu Y, Liu S, Xin H, Jiang J, Younglai E, Sun S et al (2011) Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 117:3989–3998PubMed

48.

Zhou X, Gao Q, Wang J, Zhang X, Liu K, Duan Z (2014) Linc-RNA-RoR acts as a “sponge” against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol 133:333–339PubMed

49.

Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I et al (2011) miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 71:6450–6462PubMed

50.

Panda H, Chuang TD, Luo X, Chegini N (2012) Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. J Clin Endocrinol Metab 97:E1316–E1326PubMedCentralPubMed

51.

Hiroki E, Suzuki F, Akahira J, Nagase S, Ito K, Sugawara J et al (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131:E395–E404PubMed

52.

Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T et al (2013) Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. Hum Pathol 44:2571–2580PubMed

53.

Shia J, Black D, Hummer AJ, Boyd J, Soslow RA (2008) Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 39:116–125PubMed

54.

Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517PubMed

55.

Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS et al (2014) Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol 133:340–345PubMedCentralPubMed

56.

Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ et al (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69:9038–9046PubMedCentralPubMed

57.

Liu L, Wang L, Zheng J, Tang G (2013) Leptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation. Eur J Obstet Gynecol Reprod Biol 170:198–201PubMed

58.

Xing F, Saidou J, Watabe K (2010) Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) 15:166–179

59.

Subramaniam KS, Tham ST, Mohamed Z, Woo YL, Mat Adenan NA, Chung I (2013) Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One 8:e68923PubMedCentralPubMed

60.

Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M et al (2010) The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 9:4387–4398PubMedCentralPubMed

61.

Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J (2007) Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55:1–14PubMed

62.

Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y, Yin LR (2013) MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1. FEBS J 280:3768–3779PubMed

63.

Yan GJ, Yu F, Wang B, Zhou HJ, Ge QY, Sun J et al (2014) MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1. Cancer Lett 34:39–47

64.

Husseinzadeh N, Husseinzadeh HD (2014) mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol 133:375–381PubMed

65.

Wu D, Huang HJ, He CN, Wang KY (2013) MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer 23:1191–1197PubMed

66.

Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K (2003) Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 65:159–166PubMed

67.

Ye W, Xue J, Zhang Q, Li F, Zhang W, Chen H et al (2014) MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A. Oncol Rep 32:1193–1199PubMed

68.

Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H et al (2005) Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36:1281–1288PubMed

69.

Liu P, Qi M, Ma C, Lao G, Liu Y, Liu Y et al (2013) Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B. FEBS Lett 587:2523–2529PubMed

70.

Romero-Pérez L, Castilla MÁ, López-García MÁ, Díaz-Martín J, Biscuola M, Ramiro-Fuentes S et al (2013) Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Hum Pathol 44:244–254PubMed

71.

Choi CH, Park YA, Choi JJ, Song T, Song SY, Lee YY et al (2012) Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol 126:124–131PubMed

72.

Panda H, Pelakh L, Chuang TD, Luo X, Bukulmez O, Chegini N (2012) Endometrial miR-200c is altered during transformation into cancerous states and targets the expression of ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod Sci 19:786–796PubMedCentralPubMed

73.

Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M et al (2014) MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget 5:6049–6062PubMedCentralPubMed

74.

Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497–505PubMed

75.

Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al (2003) Circulating interleukin-6 predictors survival in patients with metastatic breast cancer. Int J Cancer 103:642–646PubMed

76.

Jiang L, Meng W, Zeng J, Hu H, Lu L (2013) MiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis. Cell Biol Int 37:577–583PubMed

77.

Saydmohammed M, Joseph D, Syed V (2010) Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 110:447–456PubMed

78.

Li Y, Zhang Z, Liu X, Huang T, He W, Shen Y et al (2014) miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3. Mol Cell Biochem 388:219–231PubMed

79.

Zhou L, Cai B, Bao W, He YY, Chen XY, Yang YX et al (2011) Crosstalk between estrogen receptor and mitogen-activated protein kinase signaling in the development and progression of endometrial cancer. Int J Gynecol Cancer 21:1357–1365PubMed

80.

Pan Q, Chegini N (2008) MicroRNA signature and regulatory functions in the endometrium during normal and disease states. Semin Reprod Med 26:479–493PubMedCentralPubMed

81.

Chen X, Yan Q, Li S, Zhou L, Yang H, Yanh Y et al (2012) Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma. Cancer Lett 314:41–53PubMed

82.

Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM (2014) Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta 1845:255–265PubMedCentralPubMed

83.

Tanaka Y, Terai Y, Kawaguchi H, Fujiwara S, Yoo S, Tsunetoh S et al (2013) Prognostic impact of EMT (epithelial–mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther 14:13–19PubMedCentralPubMed

84.

Wu CY, Hung JJ, Wu KJ (2012) Linkage between Twist1 and Bmi1: molecular mechanism of cancer metastasis/stemness and clinical implications. Clin Exp Pharmacol Physiol 39:668–673PubMed

85.

Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N (2014) MicroRNA-106b modulates epithelial–mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog 53:349–359PubMed

86.

Bing L, Hong C, Li-Xin S, Wei G (2014) MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet 290:533–541PubMed

87.

Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99PubMedCentralPubMed

88.

Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ et al (2013) ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol 26:1514–1524PubMed

89.

Howe EN, Cochrane DR, Richer JK (2011) Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res 13:R45PubMedCentralPubMed

90.

Byrd AE, Brewer JW (2013) Micro(RNA)managing endoplasmic reticulum stress. UBMB Life 65:373–381

91.

Calì G, Insabato L, Conza D, Bifulco G, Parrillo L, Mirra P et al (2014) GRP78 mediates cell growth and invasiveness in endometrial cancer. J Cell Physiol 229:1417–1426PubMed

92.

Dai R, Li J, Liu Y, Yan D, Chen S, Duan C et al (2010) miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation. Biol Chem 391:791–801PubMed

93.

Duan Q, Wang X, Gong W, Ni L, Chen C, He X et al (2012) ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One 7:e31518PubMedCentralPubMed

94.

Yang YM, Liu H, Li WB (2010) Expression of Mta-1 and VEGF and their correlation in the endometrial cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26:682–684PubMed

95.

Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y et al (2014) Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS One 9:e90810PubMedCentralPubMed

96.

Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F et al (2012) microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep 27:807–812PubMed

97.

Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS et al (2012) Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130:1036–1045PubMed

98.

Bao W, Wang HH, Tian FJ, He XY, Qiu MT, Wang JY et al (2013) A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer 12:155PubMedCentralPubMed

99.

Shang C, Lu YM, Meng LR (2012) MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit 18:BR149–BR155

100.

Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H et al (2014) Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget 5:462–472PubMedCentralPubMed

101.

Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M et al (2013) Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene 32:3246–3253PubMedCentralPubMed

102.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z et al (2008) MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 110:206–215PubMed

103.

Jia W, Wu Y, Zhang Q, Gao G, Zhang C, Xiang Y (2013) Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer. Oncol Lett 6:261–267PubMedCentralPubMed

104.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMed

105.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006PubMed

106.

Uchino K, Ochiya T, Takeshita F (2013) RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol 43:596–607PubMed

107.

Soriano A, Jubierre L, Almazán-Moga A, Molist C, Roma J, de Toledo JS et al (2013) microRNAs as pharmacological targets in cancer. Pharmacol Res 75:3–14PubMed

108.

Shen Y, Lu L, Xu J, Meng W, Qing Y, Liu Y et al (2013) Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Cell Biol Int 37:1114–1121PubMed

109.

Bae J, Won M, Kim DY, Kim JH, Kim YM, Kim YT et al (2012) Identification of differentially expressed microRNAs in endometrial cancer cells after progesterone treatment. Int J Gynecol Cancer 22:561–565PubMed

110.

Bai JX, Yan B, Zhao ZN, Xiao X, Qin WW, Zhang R et al (2013) Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines. Endocrinology 154:635–665PubMed

Titel: The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review
verfasst von: Argiri Sianou
George Galyfos
Dimitra Moragianni
Panagiotis Andromidas
Georgios Kaparos
Stavroula Baka
Evangelia Kouskouni
Publikationsdatum: 01.08.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-015-3660-y

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Bildnachweise

Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Frau klebt Pflaster auf den Oberschenkel/© svetikd / Getty Images / iStock (Symbolbild mit Fotomodell), Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Junge Frau untersucht Gewebeprobe/© luchschenF / Stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Abstract

Introduction

Material and Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

HCMV seroprevalence in couples under infertility treatment

Study results on the use of different therapies for the treatment of vaginitis in hospitalised pregnant women

Renal oligo- and anhydramnios: cause, course and outcome—a single-center study

Association of the glucokinase gene promoter polymorphism -30G > A (rs1799884) with gestational diabetes mellitus susceptibility: a case–control study and meta-analysis